mingzhong sun

Prof. mingzhong sun

Dalian medical university

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 July 2015 in Oncology Letters
Verified
Journal Article
Closed access
PDF file
HQHoubao Qi
Houbao Qi
SLShuqing Liu
Shuqing Liu
CGChunmei Guo
Chunmei Guo
JWJiasheng Wang
Jiasheng Wang
FGFrederick T. Greenaway
Frederick T. Greenaway
MSmingzhong sun
mingzhong sun
Annexin A6 (AnxA6) is a member of a conserved superfamily of Ca2+-dependent membrane-binding annexin proteins. It participates in membrane and cytoskeleton organization, cholesterol homeostasis, membrane trafficking, cell adhesion and signal transduction. The expression levels of AnxA6 are closely associated with melanoma, cervical cancer, epithelial carcinoma, breast cancer, gastric cancer, prostate cancer, acute lymphoblastic leukemia, chronic myeloid leukemia, large-cell lymphoma and myeloma. AnxA6 exhibits dual functions in cancer, acting either as a tumor suppressor or promoter, depending on the type of cancer and the degree of malignancy. In several types of cancer, AnxA6 acts via Ras, Ras/MAPK and/or FAK/PI3K signaling pathways by mainly mediating PKCα, p120GAP, Bcr-Abl and YY1. In the present review, the roles of AnxA6 in different types of cancer are summarized.

1 July 2015 in Clinica Chimica Acta
Verified
Journal Article
Closed access
BWBin Wei
Bin Wei
CGChunmei Guo
Chunmei Guo
SLShuqing Liu
Shuqing Liu
MSmingzhong sun
mingzhong sun

25 May 2018 in Cell Death & Disease
Verified
Journal Article
Open access
PDF file
XSXujuan Sun
Xujuan Sun
SLShuqing Liu
Shuqing Liu
JWJinxia Wang
Jinxia Wang
BWBin Wei
Bin Wei
CGChunmei Guo
Chunmei Guo
MSmingzhong sun
mingzhong sun
As a calcium-dependent phospholipid binding annexin protein, annexin A5 (Anxa5) links to the progression, metastasis, survival, and prognosis of a variety of cancers. Current work showed ANXA5 overexpression was positively correlated with the upregulations of CRKI/II and RAC1 in hepatocarcinoma (HCC) patients’ tissues, which potentially enhanced the clinical progression and lymphatic metastasis of HCC. The role and action mechanism of ANXA5 in hepatocarcinoma was then investigated using a hepatocarcinoma Hca-P cell line, an ideal and well-established murine cell model with 100% inducible tumorigenicity of implanted mice with low (~25%) lymph node metastatic (LNM) rate. In vitro evidences indicated ANXA5 stable knockdown resulted in decreased proliferation, migration, invasion and adhesion to lymph node (LN), and increased intercellular cohesion behaviors of hepatocarcinoma Hca-P cells. Consistently, stable ANXA5 knockdown led to reduced in vivo tumorigenicity and malignancy, LNM rate and level potentials of Hca-P- transplanted mice via inhibiting CD34 and VEGF3. The levels of CRKI/II and RAC1 were reduced in tumor tissues from mice transplanted with Hca-P cells with stable ANXA5 knockdown. Molecular action investigation further showed ANXA5 downregulation apparently suppressed the expressions of molecules CRKI/II, DOCK180, RAC1 in integrin pathway, p-MEK, p-ERK, c-Myc, and MMP-9 in MEK- ERK pathway together with VIMINTIN in Hca-P cells in appropriate to knockdown extent. Collectively, Anxa5 was able to mediate HCC carcinogenesis via integrin and MEK-ERK pathways. It is of potential use in the research and treatment of HCC.

5 February 2018 in Scientific Reports
Verified
Journal Article
Open access
PDF file
CGChunmei Guo
Chunmei Guo
DZDongting Zhao
Dongting Zhao
QZQiuling Zhang
Qiuling Zhang
SLShuqing Liu
Shuqing Liu
MSmingzhong sun
mingzhong sun
Tumor metastasis is one of the main causes of hepatocellular carcinoma (HCC) high mortality. CRKL (v-crk sarcoma virus CT10 oncogene homologue (avian)-like) play important roles in tumor metastasis, however, the exact role and underlying mechanism of CRKL in HCC is still unknown. In our study, we demonstrated miR-429 negatively regulated CRKL expression via selectively binding to CRKL-3′-UTR at 3728–3735 bp site by post-transcriptionally mediating its functionality. Re-expression and silencing of miR-429 was remarkably effective in suppressing and promoting HepG2 cell migration and invasion in vitro. Knockdown or overexpression of CRKL exhibited similar effects as the overexpression or silencing of miR-429, whereas, CRKL overexpression (without the 3′-UTR) abrogated miR-429-induced inhibition on HepG2 migration and invasion. Moreover, miR-429-CRKL axis affected HepG2 migration and invasion potentials by regulating the adhesion ability, cytoskeleton F-actin expression and arrangement of HepG2. Furthermore, interference of Raf/MEK/ERK pathway and EMT contributed to miR-429-CRKL axis mediated metastasis inhibition. Nevertheless, miR-429 could not inhibit HepG2 proliferation through CRKL/c-Jun pathway. Taken together, our data demonstrated that miR-429 might function as an antimetastatic miRNA to regulate HCC metastasis by directly targeting CRKL via modulating Raf/MEK/ERK-EMT pathway. The newly identified miR-429-CRKL axis represents a novel potential therapeutic target for HCC treatment.

1 March 2021 in NeuroToxicology
Verified
Journal Article
Closed access
KWKe Wang
Ke Wang
YSYongquan Shi
Yongquan Shi
WLWei Liu
Wei Liu
SLShuqing Liu
Shuqing Liu
MSmingzhong sun
mingzhong sun

20 April 2021 in Molecular Biology Reports
Verified
Journal Article
Closed access
PDF file
QLQian Li
Qian Li
SLShuqing Liu
Shuqing Liu
JYJinsong Yan
Jinsong Yan
MSmingzhong sun
mingzhong sun
FGFrederick T. Greenaway
Frederick T. Greenaway